Saama Names Respected Clinical Technology Leader Lisa Moneymaker as CTO and Chief Product Officer

CAMPBELL, Calif. – October 24, 2022 — Saama has hired clinical technology leader Lisa Moneymaker as Chief Technology Officer and Chief Product Officer.

In this role, Lisa will drive Saama’s technology vision, product strategy, and global delivery using her 20-plus years of experience in the life sciences industry and information systems.

“Lisa is a thought leader and respected advisor throughout the pharma industry,” said Vivek Sharma, Chief Executive Officer of Saama. “Her leadership, legacy of innovation, and operational excellence will inspire our team and our customers. Combined with her vision and passion for improving lives, Lisa will drive greater outcomes for our customers and patients.”

Prior to joining Saama, Moneymaker was SVP of Clinical Operations Technology at Medidata Solutions. In this position she helped to advance the role of internal sponsor and CRO technology in support of Decentralized Clinical Trials, as the industry responded to the pressures of an increasingly remote world.

Lisa began her career at Accenture and continued as an independent consultant, gaining exposure to information systems across the pharma space. Much of her career was in support of Amgen, developing systems within its global development organization, which gained her exposure and recognition as a subject matter expert within pharma information systems. While at Amgen, she was given leadership roles within TransCelerate Biopharma, driving industry innovation through delivery of the Shared Investigator Platform and the Investigator Registry.

Lisa is a graduate of University of Southern California and holds a BS in Biomedical Biochemical Engineering.

About Saama

Saama develops life science solutions that accelerate clinical and commercial development. Today, more than 50 biotech companies – including many of the top 20 pharmaceutical companies – use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate more than 1,500 studies, including the clinical trial led to the world’s first COVID-19 vaccine. LSAC’s rich applications facilitate unprecedented and authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Application (NDAs) more efficiently and bring treatments to patients sooner. Discover more at and follow @SaamaTechLine on Twitter.

Victoria Clayton
[email protected]